# Retatrutide FAQ: Common Questions Answered from Trial Data > Retatrutide FAQ: 22 common questions answered from published trial data. Investigational compound — not approved, not a clinical service. 22 common questions answered from the Phase 1b, Phase 2, and ongoing Phase 3 published record. ## Does Retatrutide target belly fat? Retatrutide reduces total body fat, including visceral fat (the fat stored around internal organs, often called belly fat). In the 48-week Phase 2 obesity trial, 12 mg produced a mean -24.2% total body-weight change vs -2.1% with placebo [1]. The MASLD liver-fat substudy showed -82.4% reduction in liver fat at 24 weeks at 12 mg [5], consistent with visceral/ectopic fat reduction. ## Are there dose-dependent differences in weight loss outcomes with retatrutide? Yes — clearly. The Phase 2 obesity trial compared 1, 4, 8, and 12 mg arms against placebo over 48 weeks. Weight loss was dose-dependent: larger doses produced progressively larger body-weight reductions, with the highest dose arm reaching -24.2% mean body weight change vs -2.1% placebo [1]. Adverse events, including GI symptoms and heart-rate increases, were also dose-dependent. ## How does retatrutide compare to tirzepatide in terms of weight loss? No head-to-head published trial exists as of mid-2026. Indirect comparison: retatrutide's Phase 2 obesity data show -24.2% at 12 mg/48 weeks [1]; tirzepatide's Phase 3 data show approximately 20-22% weight loss at highest approved doses over 72 weeks. Populations, durations, and titration schedules differ, making direct comparison unreliable. A registered Phase 3 head-to-head trial between the two compounds is ongoing; results are not yet published. ## How does retatrutide help regulate blood sugar levels and aid in weight loss? Retatrutide's GLP-1 receptor arm stimulates glucose-dependent insulin secretion (insulin released only when blood glucose is elevated). The GIP receptor arm adds insulinotropic and adipose-signaling effects. The glucagon receptor arm increases energy expenditure and hepatic lipid breakdown. Combined, these three signals reduce caloric intake, improve insulin sensitivity, and increase calorie burning. In the Phase 2 T2D trial, HbA1c (average blood glucose marker) fell by -2.02% at 12 mg vs -0.01% placebo at 24 weeks [2]. ## What is the significance of retatrutide achieving 28% weight loss in TRIUMPH-1? Phase 3 TRIUMPH-1 results have not been published as of mid-2026 — the 28% figure circulating in press reports appears to refer to early interim signals or analyst projections, not published data. The published Phase 2 figure is -24.2% at 12 mg/48 weeks [1]. This site reports only published, peer-reviewed data. When TRIUMPH-1 results are published, this page will be updated. ## What does retatrutide do? Retatrutide simultaneously activates three hormone receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (insulin enhancement, adipose effects), and GCGR (energy expenditure, liver lipid breakdown). In clinical trials, this triple activation produced large weight losses (-24.2% at 12 mg/48 weeks in obesity [1]), blood-sugar improvements (-2.02% HbA1c in T2D [2]), and substantial liver-fat reduction (-82.4% at 24 weeks in MASLD [5]). A 2025 review characterized these results as a step-change versus earlier incretin therapies [6]. ## How does retatrutide work? Retatrutide is a single synthetic 39-amino-acid peptide that binds all three class-B GPCRs: GLP-1R, GIPR, and GCGR. GLP-1R agonism slows gastric emptying and suppresses appetite. GIPR agonism enhances post-meal insulin release and has adipose effects. GCGR agonism increases energy expenditure via thermogenesis and speeds up hepatic fat breakdown. Cryo-EM structural data (Li et al., 2024) confirmed atomic-level binding at all three receptors [3]. The three signals converge on cAMP/PKA downstream signaling in their respective tissues. ## How to reconstitute retatrutide? In clinical trials, retatrutide was provided as a pre-formulated investigational drug in ready-to-use vials — participants did not reconstitute it themselves. No approved reconstitution standard exists for retatrutide in any non-trial context. This site does not provide preparation instructions for gray-market research-labeled material; such products are unverified for identity, purity, and sterility. See the [effects and safety page](/effects) for the safety caution on gray-market sources. ## Is retatrutide FDA approved? No. As of mid-2026, retatrutide is not approved by the FDA or any regulatory agency worldwide. It is an investigational compound in Phase 3 clinical trials (Eli Lilly's TRIUMPH program). It has no approved indication, no approved labeling, and is not available as a commercial prescription product. Approval, if any, would follow positive Phase 3 results and an FDA review process — both of which are pending. ## When will retatrutide be available? No confirmed timeline as of mid-2026. Retatrutide availability as an approved product depends on TRIUMPH Phase 3 data readouts and FDA review. Eli Lilly has not published a regulatory submission timeline. Analysts estimate a potential NDA filing in 2026-2027 if Phase 3 readouts are positive, but this is speculative. Clinical trial enrollment is the only legal pathway to access it under a physician investigator's oversight. ## How to take retatrutide? In Phase 2 trials, retatrutide was administered as a subcutaneous (under-the-skin) injection once weekly, with dose escalation from lower starting doses over several weeks to manage GI side effects [1, 2, 4]. This site does not provide personal guidance on how to use retatrutide. It is an investigational compound; outside a clinical trial, there is no approved dosing, no approved formulation, and no regulatory framework for its use. ## How long does retatrutide take to work? In the Phase 2 obesity trial, body-weight changes were observed progressively from the first weeks, with the largest effects accumulating over 24-48 weeks at the highest doses [1]. The ~6-day half-life means steady-state plasma concentrations build over approximately 4-5 weekly doses. Community members report noticing scale movement within the first few weeks, though individual variation is significant. See [how long does retatrutide take to work](/how-long-to-work) for a full timeline breakdown from trial data. ## Is retatrutide better than tirzepatide? No published head-to-head trial has answered this question. Retatrutide's Phase 2 weight-loss figures are numerically larger than tirzepatide's Phase 3 approved-dose figures in indirect comparison, but different trial populations, durations, and titration schedules make that comparison unreliable. The glucagon receptor arm in retatrutide adds an energy-expenditure mechanism tirzepatide lacks — whether that translates to clinical superiority in a head-to-head trial remains to be seen. The registered Phase 3 comparative trial is ongoing. ## How much retatrutide per week? In Phase 2 trials, participants were assigned to doses of 1, 4, 8, or 12 mg once weekly (obesity trial) or escalating doses up to 12 mg once weekly (T2D trial). These are study-design facts — they describe how the clinical trials were structured, not a recommended amount for any individual. Retatrutide is not approved; no standard dose exists. All dosing figures from this site are attributed to specific published trials [1, 2, 4]. ## How to mix retatrutide with bacteriostatic water? Clinical trial supplies of retatrutide were provided as ready-to-use pre-formulated vials. Trial participants did not mix or reconstitute the compound. This site does not provide mixing instructions for gray-market retatrutide powder. Products sold through gray-market research channels are unverified for identity and purity, and the FDA has issued warning letters to such vendors. See the safety cautions on the [effects page](/effects). ## How to switch from tirzepatide to retatrutide? No published clinical guidance exists on transitioning between these two compounds. Tirzepatide is an approved drug with labeled dosing and clinical indications; retatrutide is investigational with no approved labeling. This site does not advise on medication switching or sequencing — that decision, for an approved drug like tirzepatide, would require a prescribing physician. ## Is retatrutide a GLP-3? No — there is no GLP-3 receptor. "GLP-3" is a misnomer circulating in popular press and online discussion. Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors. The three-receptor combination is sometimes loosely called a "triple GLP" in non-scientific press, which appears to have spawned the inaccurate GLP-3 label. Retatrutide's receptor targets are GLP-1R, GIPR, and GCGR — all confirmed by cryo-EM structural data [3]. ## Is retatrutide available? Retatrutide availability is limited to clinical trial enrollment as of mid-2026. It is not approved for prescription use anywhere in the world. Gray-market research-labeled material exists — but such products are unregulated, unverified for identity and purity, and the FDA has issued warning letters to vendors. Enrollment in Eli Lilly's TRIUMPH Phase 3 trials is the only regulated pathway to access retatrutide under clinical oversight. ## What is retatrutide used for? Retatrutide is being studied for obesity (as a standalone treatment), type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), obstructive sleep apnea, knee osteoarthritis, cardiovascular outcomes, and chronic kidney disease (CKD) in the TRIUMPH Phase 3 program [10]. Phase 2 data confirmed large weight loss, HbA1c reduction, and dramatic liver-fat reduction. There is no approved use. A 2025 review characterized it as a potential step-change in obesity pharmacotherapy [6]. ## What receptors does retatrutide target? Retatrutide targets three receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). All three are class-B GPCRs (a family of cell-surface receptors). Cryo-EM structural data resolved retatrutide's binding at all three receptors at 2.68/3.26/2.84 Å resolution (Li et al., Cell Discovery 2024) [3]. Relative potency: ~8.9x at GIPR, ~0.3x at GCGR, ~0.4x at GLP-1R compared to native hormones. ## Is retatrutide legal? The compound itself is not a scheduled substance in the US or most jurisdictions as of mid-2026 — it is not a controlled drug. However, it is an unapproved drug product, and selling it as a prescription drug or compounding it without authorization may violate FDA regulations. The FDA issued warning letters to retatrutide vendors in 2025 under the Federal Food, Drug, and Cosmetic Act. Obtaining it for injection outside a clinical trial involves gray-market material with significant legal ambiguity and no clinical oversight. ## Retatrutide cost Retatrutide has no approved commercial price as of 2026 — it is not on the market. Analysts project that, if approved, pricing would be in the range of other GLP-1-class anti-obesity medicines. Gray-market research-labeled retatrutide is sold at varying prices online, but purchasing it falls outside any regulated pricing, quality, or safety framework. This site does not link to or recommend any vendor. ## Retatrutide availability As of mid-2026, retatrutide availability is limited to clinical trial enrollment. The TRIUMPH Phase 3 program is ongoing. No regulatory approval has been granted. An FDA NDA submission timeline has not been publicly confirmed by Eli Lilly. For updates on trial enrollment or expected approval timelines, ClinicalTrials.gov (search NCT06383390, NCT05929066, and related TRIUMPH trial numbers) is the authoritative source. ## How often do you take retatrutide? In all Phase 1b and Phase 2 clinical trials, retatrutide was administered as a once-weekly subcutaneous injection [1, 2, 4]. The ~6-day half-life supports weekly dosing intervals, maintaining stable plasma concentrations between doses. This is a study-design fact. There is no approved dosing schedule; no guidance on frequency is offered here for use outside a clinical trial. --- Trial data on one investigational compound — published, cited, and held by no clinic and no vendor.